Skip to main content

Advertisement

Table 1 Patient demographics and baseline characteristics, ITT population

From: Comparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids

  VI 25 mcg OD (N = 115) SAL 50 mcg BD (N = 116) Placebo (N = 116) Total (N = 347)
Age, years 41.0 (17.81) 41.1 (16.84) 41.7 (16.64) 41.3 (17.06)
Female sex, n (%) 68 (59) 77 (66) 59 (51) 204 (59)
Duration of asthma, years 17.61 (13.54) 19.41 (14.87) 18.43 (13.33) 18.49 (13.91)
Screening pre-bronchodilator FEV1 (ml) 2133 (631.4) 2078 (591.7) 2204 (653.0) 2139 (626.2)
Screening % predicted FEV1 66.6 (12.84) 65.8 (12.72) 65.9 (12.03) 66.1 (12.50)
Screening % reversibility FEV1 28.2 (16.36) 26.2 (13.82) 30.0 (16.58) 28.1 (15.67)
Screening absolute FEV1 reversibility (ml) 577.1 (344.79) 533.7 (313.85) 650.6 (383.34) 587.2 (350.84)
Baseline pre-dose FEV1 (ml) 2264 (619.7) 2174 (587.7) 2250 (704.0) 2229 (637.9)
Baseline rescue-free 24-hour periods (%) 7.5 (19.49) 8.0 (19.48) 4.9 (16.21) NA
Baseline symptom-free periods (%) 5.1 (15.79) 6.0 (16.20) 2.4 (11.11) NA
  1. Values are mean (SD) unless otherwise stated.
  2. BD: twice-daily; FEV1: forced expiratory volume in one second; ITT: intent-to-treat; OD: once-daily; SAL: salmeterol; SD: standard deviation; VI: vilanterol.